Avicenna.AI SAS secured a further $7.5 million in series A funding, bringing the total aggregated investment in the company so far to $10.4 million. The round was backed by the two existing Paris-based investors: Cemag Invest SAS and Innovacom Gestion SAS. “Thanks to this funding, we are now able to ramp deployment of our software platform around the world, as well as diversify our offering into new areas of medicine,” Cyril Di Grandi, CEO and co-founder of Avicenna.AI SAS, told BioWorld.
The U.S. FDA granted 510(k) clearance to Hyperfine Inc. for improved artificial intelligence (AI)-powered software for its Swoop portable magnetic resonance imaging (MRI) device. The company launched the new software this week.
Cydar Medical Ltd. raised $11.5 million (£9.3 million) in a series A funding round which will allow it to advance its artificial intelligence (AI) surgical maps platform and bolster its ongoing commercial expansion.
With an eye toward the future, the U.S. Patent and Trademark Office (USPTO) is seeking comment on artificial intelligence (AI) technologies and inventorship issues that may arise as AI takes on a bigger role in innovation.
Shukun Technology Inc.’s recently approved AI-based system to assess coronary arteries can get results in minutes, significantly speeding up diagnostics.
With an eye toward the future, the U.S. Patent and Trademark Office (USPTO) is seeking comment on artificial intelligence (AI) technologies and inventorship issues that may arise as AI takes on a bigger role in innovation.
Bayer AG acquired Blackford Analysis Ltd., a British developer of artificial intelligence systems that help make diagnoses using medical images in the U.K. and U.S. The companies did not disclose any financial details. “This deal is part of our strategy to drive innovation in radiology, including the development and adoption of AI within the workflow, with the goal of ultimately improving patient care and advance our position in digital medical imaging,” Stefan Oelrich, a board member at Bayer AG and president of Bayer’s pharmaceutical division, told BioWorld.
Eyenuk Inc. is significantly extending the scope of its artificial intelligence system for the automatic analysis of retinal images, adding the diagnosis of age-related macular degeneration (AMD) and glaucoma to the EU approved uses of Eyeart AI.
Precisedx Inc.’s digital artificial intelligence (AI) platform better predicts the recurrence of early-stage breast cancer within six years than traditional testing, a study published in Breast Cancer Research found. Understanding which patients with early-stage disease face significant risk of their cancer returning is important for guiding selection of treatment. The system reduces the variability inherent in histological characterization and grading of breast cancer (BC) today, thereby improving prognostic accuracy.
